Nureca IPO
Nureca IPO — date, price band, lot size & details 2021
Nureca listed on 25 Feb 2021 at ₹615, 53.8% above the ₹400 issue price.
Nureca sells home healthcare and wellness products, mainly under its Dr Trust brand, through online channels. Its total income rose to Rs 99.49 crore in FY2020.
Stock price
Nureca is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 11 November.
- Open 15 Feb 2021
- Close 17 Feb 2021
- Allotment 23 Feb 2021
- Refund/credit 24 Feb 2021
- Listing 25 Feb 2021
Issue summary
The terms of the offer, as filed.
| IPO Dates | 15 to 17 Feb, 2021 |
|---|---|
| Price Band | ₹396 – ₹400 |
| Face Value | ₹10 |
| Lot Size | 35 Shares |
| Issue Size | ₹100 Cr |
| Sale Type | Fresh capital only |
| Listing On | BSE, NSE |
| Employee Discount | Rs 20.00 per share |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,000 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 35 shares at the ₹400 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 35 | ₹14,000 |
| Retail (max) | 14 | 490 | ₹1,96,000 |
| S-HNI (min) | 15 | 525 | ₹2,10,000 |
| S-HNI (max) | 71 | 2,485 | ₹9,94,000 |
| B-HNI (min) | 72 | 2,520 | ₹10,08,000 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 6
- 01Total income rose from Rs 20.07 crore in FY2018 to Rs 99.49 crore in FY2020.
- 02Total income was Rs 122.97 crore in the six months to 30 September 2020, already above the full FY2020 figure.
- 03Profit after tax was Rs 36.18 crore in the six months to 30 September 2020, against Rs 6.40 crore in all of FY2020.
- 04The whole Rs 100 crore issue was fresh capital, so the money after expenses came to the company.
- 05The P/E was 5.53 at the upper band of Rs 400, based on post-issue EPS of Rs 72.36 as shown at the source.
- 06Total borrowing was only Rs 8.02 crore on 30 September 2020.
Risks · 6
- 01Profit of Rs 36.18 crore in the six months to 30 September 2020 was far above Rs 6.23 crore in FY2019 and Rs 6.40 crore in FY2020, so the latest level may not hold.
- 02The pre-issue P/E was 46.89 at Rs 400, based on FY2020 EPS of Rs 8.53.
- 03The company started operations only in Fiscal 2017, so its track record is short.
- 04Assets were only Rs 102.49 crore on 30 September 2020, and sales depend heavily on e-commerce partners.
- 05Net worth was small, at Rs 14.93 crore on 31 March 2020, before the recent profits.
- 06Promoter holding fell from 93.33% before the issue to 70% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Nureca offer document.
| Metric | 30 Sep 2020 | 31 Mar 2020 | 31 Mar 2019 | 31 Mar 2018 |
|---|---|---|---|---|
| Assets | 102.49 | 33.88 | 23.52 | 7.02 |
| Total Income | 122.97 | 99.49 | 61.98 | 20.07 |
| Profit After Tax | 36.18 | 6.40 | 6.23 | 3.11 |
| EBITDA | 50.01 | 9.76 | 9.14 | 4.39 |
| NET Worth | 51.65 | 14.93 | 7.95 | 1.72 |
| Reserves and Surplus | 44.65 | 14.92 | 7.94 | 1.71 |
| Total Borrowing | 8.02 | 9.15 | 0.00 | 0.00 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Nureca RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Nureca IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹8.53 | ₹72.36 |
| P/E Ratio (x) | 46.89 | 5.53 |
| Market Cap at Offer Price (₹ Cr) | ₹1,696.60 | ₹200.00 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹400 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹75.00 Cr of the issue is earmarked to named objects.
About the company
Its range covers chronic device products, orthopaedic products, mother and child products, nutrition supplements and lifestyle products. These help customers keep track of chronic ailments at home.
It is a digital first company. Products are sold through e-commerce players, distributors and retailers, and through its own website drtrust.in. Dr Trust is its main brand.
The IPO was Rs 100 crore and was entirely fresh issue. Rs 75.00 crore of the proceeds was planned for incremental working capital.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Nureca IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
ITI Capital Ltd
4 issues handledBest listing: Waaree Energies (+66.3%). Weakest: Suraj Estate Developers (-5.6%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Nureca?
The current Grey Market Premium is ₹0.
What is the Nureca IPO price band?
₹396 to ₹400, on a face value of ₹10.
When is the allotment?
The basis of allotment is 23 February 2021, with listing on 25 February 2021.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
